4 minute read
May 31, 2023

Gepotidacin: A Potential First-In-Class Oral Antibiotic With Recent Positive Ph. III Data

gepotidacin

oral BID antibacterial Type II topoisomerase inhibitor Ph. III for uncomplicated UTIs from unbiased antibacterial screen + opt. ECCMID, April 2023 Glaxo (GSK), Stevenage, UK

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in